从患者视角看中枢性尿崩症:管理、心理共病及疾病更名:一项国际网络调查结果
该国际网络横断面匿名调查由内分泌科医生和患者代表设计,于2021年8月23日至2022年2月7日纳入1034例中枢性尿崩症患者,评估其管理、并发症、心理共病及更名意愿。结果显示去氨加压素相关低钠血症住院率26%,64%报告生活质量下降,80%遭遇误认为糖尿病,85%支持更名。
要点
- 994例使用去氨加压素患者中260例(26%)因低钠血症住院。
- 患者常规省略或延迟去氨加压素以允许间歇性水利尿,低钠血症患病率显著低于不了解此方法者(OR 0.55,95%CI 0.39-0.77;p=0.0006)。
- 535例因任何医疗原因住院的患者中71例(13%)在禁食状态下未接受去氨加压素且无静脉补液,报告脱水症状。
核心结论
- 这是目前最大规模的中枢性尿崩症患者调查,报告了治疗相关副作用、住院期间管理不当、心理共病的高患病率以及对疾病更名的明确支持。
- 数据首次提示常规省略或延迟去氨加压素的价值。
研究设计与样本
- 横断面、网络、匿名调查,由内分泌科医生和患者代表设计。
- 于2021年8月23日至2022年2月7日纳入1034例中枢性尿崩症患者。
- 91例(9%)为儿童和青少年(37例[41%]女孩,54例[59%]男孩;中位年龄10岁[IQR 6-15]),943例(91%)为成人(757例[80%]女性,186例[20%]男性;中位年龄44岁[34-54])。
- 488例(47%)为孤立性垂体后叶功能障碍,546例(53%)为垂体前叶和后叶联合功能障碍。
- 主要病因:特发性315例(30%),肿瘤和囊肿(术前217例[21%];术后254例[25%])。
主要发现
- 994例使用去氨加压素治疗的患者中,260例(26%;95%CI 0.23-0.29)发生低钠血症导致住院。
- 常规省略或延迟去氨加压素以允许间歇性水利尿的患者,低钠血症患病率显著低于不了解此方法的患者(OR 0.55 [95%CI 0.39-0.77];p=0.0006)。
- 535例因任何医疗原因住院的患者中,71例(13%;95%CI 0.10-0.16)在禁食状态下未接受去氨加压素且无静脉补液,报告脱水症状。
- 660例(64%;95%CI 0.61-0.67)报告生活质量下降,369例(36%;95%CI 0.33-0.39)有主观上与中枢性尿崩症相关的心理变化。
- 823例(80%;95%CI 0.77-0.82)遇到医疗保健专业人员将中枢性尿崩症与糖尿病混淆的情况;884例(85%;95%CI 0.83-0.88)支持更名,最受青睐的替代名称为加压素缺乏症和精氨酸加压素缺乏症。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Central diabetes insipidus is a rare neuroendocrine condition. Data on treatment-associated side-effects, psychological comorbidities, and incorrect management are scarce. The aim of this study was to investigate patients' perspectives on their disease. METHODS: This study used a cross-sectional, web-based, anonymous survey, developed by endocrinologists and patient representatives, to collect the opinions of patients with central diabetes insipidus on management and complications of their disease, psychological comorbidities, degree of knowledge and awareness of the condition among health-care professionals, and renaming the disease to avoid confusion with diabetes mellitus (diabetes). FINDINGS: Between Aug 23, 2021, and Feb 7, 2022, 1034 patients with central diabetes insipidus participated in the survey. 91 (9%) participants were children and adolescents (37 [41%] girls and 54 [59%] boys; median age 10 years [IQR 6-15]) and 943 (91%) were adults (757 [80%] women and 186 [20%] men]; median age 44 years [34-54]). 488 (47%) participants had isolated posterior pituitary dysfunction and 546 (53%) had combined anterior and posterior pituitary dysfunction. Main aetiologies were idiopathic (315 [30%] of 1034 participants) and tumours and cysts (pre-surgical 217 [21%]; post-surgical 254 [25%]). 260 (26%; 95% CI [0·23-0·29]) of 994 patients on desmopressin therapy had hyponatraemia leading to hospitalisation. Patients who routinely omitted or delayed desmopressin to allow intermittent aquaresis had a significantly lower prevalence of hyponatraemia compared with those not aware of this approach (odds ratio 0·55 [95% CI 0·39-0·77]; p=0·0006). Of patients who had to be hospitalised for any medical reason, 71 (13%; 95% CI 0·10-0·16) of 535 patients did not receive desmopressin while in a fasting state (nil by mouth) without intravenous fluid replacement and reported symptoms of dehydration. 660 (64%; 0·61-0·67) participants reported lower quality of life, and 369 (36%; 0·33-0·39) had psychological changes subjectively associated with their central diabetes insipidus. 823 (80%; 0·77-0·82) participants encountered a situation where central diabetes insipidus was confused with diabetes mellitus (diabetes) by health-care professionals. 884 (85%; 0·83-0·88) participants supported renaming the disease; the most favoured alternative names were vasopressin deficiency and arginine vasopressin deficiency. INTERPRETATION: This is the largest survey of patients with central diabetes insipidus, reporting a high prevalence of treatment-associated side-effects, mismanagement during hospitalisation, psychological comorbidities, and a clear support for renaming the disease. Our data are the first to indicate the value of routinely omitting or delaying desmopressin. FUNDING: Swiss National Science Foundation, Swiss Academy of Medical Sciences, and G&J Bangerter-Rhyner-Foundation.
引用
- Atila C, Loughrey PB, Garrahy A, et al. Central diabetes insipidus from a patient's perspective: management, psychological co-morbidities, and renaming of the condition: results from an international web-based survey. Lancet Diabetes Endocrinol. 2022. PMID: 36007536. doi:10.1016/S2213-8587(22)00219-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。